IOPAMIDOL INJECTION USP 76 %
IOPAMIDOL : 76 % · DIN 02231261 · HOSPIRA HEALTHCARE ULC
Health Canada status: CANCELLED PRE MARKET
What is IOPAMIDOL INJECTION USP?
IOPAMIDOL INJECTION USP 76 % contains IOPAMIDOL : 76 %. It is listed in the Health Canada Drug Product Database under DIN 02231261, held by HOSPIRA HEALTHCARE ULC, supplied as SOLUTION for INTRAVASCULAR administration. Health Canada currently lists it as cancelled pre market, status dated 26-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IOPAMIDOL INJECTION USP used for?
null
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02231261 |
|---|---|
| Brand name | IOPAMIDOL INJECTION USP |
| Generic / active ingredient | IOPAMIDOL : 76 % |
| Manufacturer | HOSPIRA HEALTHCARE ULC |
| Strength | 76 % |
| Dosage form | SOLUTION |
| Route of administration | INTRAVASCULAR |
| Schedule | Ethical |
| ATC code | V08AB04 IOPAMIDOL |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 26-Nov-2018 |
How is it administered?
Dosage varies by indication. For anaerobic infections: 500 mg every 8 hours. For trichomoniasis: 2 g single dose or 250 mg TID for 7 days. Administer with food to minimize GI upset.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
null
Contraindications
Contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Contraindicated in the first trimester of pregnancy.
Warnings and precautions
Convulsive seizures and peripheral neuropathy have been reported. Use with caution in patients with CNS diseases. Avoid alcohol during therapy and for 48 hours after.
What can be used instead?
Other Canadian products sharing ATC code V08AB04 IOPAMIDOL. 5 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ISOVUE 200 INJECTION | 41 % | SOLUTION | BRACCO IMAGING CANADA | MARKETED | DIN 02229013 |
| ISOVUE 300 INJECTION | 61 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02229021 |
| ISOVUE 370 INJECTION | 76 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02229048 |
| ISOVUE MULTIPACK-300 | 61 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02242122 |
| ISOVUE MULTIPACK-370 | 76 % | LIQUID | BRACCO IMAGING CANADA | MARKETED | DIN 02242121 |
| IOPAMIDOL INJECTION USP | 61 % | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED PRE MARKET | DIN 02231260 |
| ISOVUE 128 INJ 26% | 26 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01958011 |
| ISOVUE 128 INJECTION | 26 % | LIQUID | BRACCO IMAGING CANADA | CANCELLED POST MARKET | DIN 02229005 |
| ISOVUE 200 INJ 41% | 41 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01958003 |
| ISOVUE 300 INJ 61% | 61 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01958976 |
Who else supplies IOPAMIDOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IOPAMIDOL appears in 57 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.